Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502754 | 1.00 | LPL (0.41) | LPLLIPGEGFRRECQLLOX | |
| SCHEMBL29502732 | 0.80 | UHRF1 (0.42) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL253320 | 0.80 | UHRF1 (0.42) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL614168 | 0.79 | NOS3 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29419367 | 0.79 | NOS3 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23496480 | 0.79 | LPL (0.41) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL17053327 | 0.79 | LPL (0.41) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL613614 | 0.79 | LPL (0.47) | LPLLIPGEGFRLOXL2CA1 | |
| SCHEMBL12069605 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29381650 | 0.79 | LPL (0.47) | LPLLIPGEGFRLOXL2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025235740-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-12065437-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| WO-2007030359-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | LPL 3014/4885LIPG 1960/4885EGFR 3869/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | LPL 4706/4885LIPG 4135/4885EGFR 950/4885 |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | LPL 3376/4885LIPG 675/4885EGFR 3084/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | LPL 1919/4885LIPG 2219/4885EGFR 1732/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | LPL 4786/4885LIPG 3438/4885EGFR 1962/4885 |
| US-12065437-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | LPL 2118/4885LIPG 1231/4885EGFR 1560/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | LPL 4658/4885LIPG 4105/4885EGFR 1792/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | LPL 2118/4885LIPG 1231/4885EGFR 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.